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applicationsThe multidimensional cargo of extracellular vesicles (EV) released in urine is a reflection of the
pathophysiological processes occurring within their cells and tissues of origin in the urogenital
system. Here, we describe a step-by-step protocol for density-based separation of urinary EV
with high specificity and repeatability. The implementation of integrative omics allows the study
of the molecular complexity of highly purified urinary EV, supporting the identification of EV-
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SUMMARY
The multidimensional cargo of extracellular vesicles (EV) released in urine is a
reflection of the pathophysiological processes occurring within their cells and tis-
sues of origin in the urogenital system. Here, we describe a step-by-step protocol
for density-based separation of urinary EV with high specificity and repeatability.
The implementation of integrative omics allows the study of the molecular
complexity of highly purified urinary EV, supporting the identification of EV-spe-
cific functions and biomarkers.
For complete details on the use and execution of this protocol, please refer to
Dhondt et al. (2020).
BEFORE YOU BEGIN
Preparation of Size-Exclusion Chromatography (SEC) Columns
Timing: 6–8 h
Prepare size-exclusion chromatography (SEC) columns at least 1 d before use, because washing the
Sepharose CL-2B resin by gravity sedimentation takes several hours.
1. Transfer the Sepharose CL-2B resin to a sterile glass laboratory bottle. Wait at least 2 h to obtain
complete gravity sedimentation of the resin (Figure 1A). Decant the supernatant and replace with
1 volume of PBS per 3 volumes of resin. Mix thoroughly. Repeat this washing step twomore times.
Do not decant the liquid after the final washing step.
2. Place a 1 cm2 piece of nylon-net filter with a 20-mmpore size on the bottom of a 10 mL disposable
syringe (Figure 1B).
3. Clamp the syringe to a laboratory stand and pipet the washed Sepharose CL-2B resin into the sy-
ringe (Figure 1C). Let the resin settle and add more until the syringe is filled with exactly 10 mL of
stacked resin (Figure 1D). Make sure the column never dries out.
4. Close the lower opening of the syringe with a closing cone and the upper opening with Parafilm
and store upright in a rack at 4C until use.
SEC columns can be stored at 4 C for up to 1 week.
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CRITICAL: The recommended syringe for in-house preparation of SEC columns has a
concentric Luer slip nozzle and an internal diameter of 14.8 mm. Since the diameter of
the SEC column and the location of the syringe nozzle impact the recovery efficiency
of EV, we recommend the use of a syringe with identical dimensions if researchers are
unable to use this particular syringe.
Alternatives: Commercial SEC columns can be used as an alternative to in-house made SEC
columns. The qEVoriginal-70 nm (IZON Science - Cat#SP1) is an off-the-shelf SEC column with
identical characteristics as the in-house made column presented in this protocol.
Preparation of the Ultracentrifuge
Timing: 5 min
Prior to Urinary EV Separation, place the SW 32.1 Ti rotor and buckets in a cold room at 4 C. Turn on
the ultracentrifuge and cool down to 4 C.
KEY RESOURCES TABLE
Figure 1. Preparation of SEC Columns
(A) Sepharose CL-2B resin after gravity sedimentation.
(B) A nylon net (20 mm pore size) is placed on the bottom of a disposable 10 mL syringe.
(C) Washed resin in transferred into the syringe.
(D) A SEC column filled with exactly 10 mL of stacked resin.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Alix Cell Signaling Technology Cat#2171S
TSG-101 Santa Cruz Biotechnology Cat#sc-7964
Flotillin-1 BD Biosciences Cat#610820
Syntenin-1 Abcam Cat#ab133267
CD9 Cell Signaling Technology Cat#D3H4P
PODXL Abcam Cat#ab150358
AQP2 ThermoFisher Scientific Cat#PA5-38004
UPK1B Sigma-Aldrich Cat#HPA031800
PSA/KLK3 Cell Signaling Technology Cat#D11E1
GM130 BD Biosciences Cat#610822
THP Santa Cruz Biotechnology Cat#sc-20631
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
PMP70 Sigma-Aldrich Cat#P0497
Sheep anti-mouse HRP-linked Ab GE Healthcare life
sciences
Cat#NA931V




Urine Human Ethical Committee of Ghent University
Hospital approval EC/2015/0260
Chemicals, Peptides, and Recombinant Proteins
OptiPrep (60% w/v) iodixanol Axis-Shield Cat#AXS-1114542
Sucrose Sigma-Aldrich Cat#S0389
EDTA (Titriplex III) Merck Millipore Cat#1084180100
Tris base Sigma-Aldrich Cat#T6066
HCl (standardized solution 5.0 N) VWR Cat#35638.K2
Ultrapure water Invitrogen Cat#AM9932
PBS (pH 7.2) ThermoFisher Scientific Cat#20012019
Sepharose CL-2B GE Healthcare Cat#17014001
Critical Commercial Assays




EV-TRACK (Van Deun et al., 2017) EV-TRACK ID: EV190064
ProteomeXchange (Vizcaı́no et al., 2014) Dataset identifier: PXD015289
GEO (Edgar, 2002) Dataset identifier: GSE131689
Other
100 mL urine collection container with
screw cap (sterile)
Sarstedt Cat#75.562.105
1.5 mL Eppendorf Safe-Lock
microcentrifuge tubes (sterile)
Sigma-Aldrich Cat#EP022363212
5 mL Eppendorf tubes (sterile) Sigma-Aldrich Cat#EP0030119460
17 mL Thinwall polypropylene tube Beckman Coulter Cat#337986
Conical 50 mL polypropylene tubes
(sterile)
Greiner Bio One Cat#210261
Centricon Plus-70 centrifugal filter units
(10 kDa MWCO)
Merck Millipore Cat#UFC701008
Amicon Ultra-2 centrifugal filter units
(10 kDa MWCO)
Merck Millipore Cat#UFC201024
10 mL Disposable syringe (sterile) Romed Cat#3SYR-10ML
Combi-Stopper closing cones B Braun Cat#4495101
Parafilm M laboratory film Bemis Company Cat#PM-996
Nylon-net filters (20.0 mm pore size) Merck Millipore Cat#NY2002500
Bottle-top vacuum filters (0.22 mm pore
size)
Sigma-Aldrich Cat#CLS430624
Optima XPN-80 Ultracentrifuge Beckman Coulter Cat#A99839
SW 32.1 Ti Swinging-Bucket Rotor and SW
32 Ti Rotor Bucket Set
Beckman Coulter Cat#369651
Biomek 4000 Laboratory Automation
Workstation
Beckman Coulter Cat#A99749
(Continued on next page)
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MATERIALS AND EQUIPMENT
We recommend that all materials are prepared in a class II laminar flow cabinet to avoid contamina-
tion. Sterile, omics-grade resources are used for all steps.
Density Gradient Buffers
 To prepare 1 L of density gradient buffer 1, dissolve 85.58 g sucrose, 1.75 g EDTA and 7.27 g Tris
in 800 mL of ultrapure water at 20C–25C (use magnetic stirrer). Adjust the pH to 7.4 with HCl (5
M). Dilute the buffer to 1 L with ultrapure water.
 Filter the buffer by passing it through a vacuum-connected 0.22-mm bottle-top filter on top of a
sterile bottle.
 To prepare 1 L of density gradient buffer 2, dissolve 85.58 g sucrose, 0.29 g EDTA and 1.21 g Tris
in 800 mL of ultrapure water at 20C–25C (use magnetic stirrer). Adjust the pH to 7.4 with HCl (5
M). Dilute the buffer to 1 L with ultrapure water.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Magnetic stirrer N/A N/A
P100 - P5000 Manual pipettes N/A N/A
P100 - P5000 Pipette tips (sterile) N/A N/A
Electronic pipettor BrandTech Scientific Cat#26330
5 mL and 25 mL Serological pipettes nerbe plus Cat#12-441-9105
Cat#12-481-9102
Cooled benchtop centrifuge with
swinging-bucket rotor
Eppendorf Cat#5811000320




Vacuum pump N/A N/A
Laboratory stand with three-prong
extension clamps
VWR Cat#470135-122
Vortex mixer N/A N/A
Multi-well microplate reader Biotek Cat#SynergyHTX
Nunc MicroWell 96-Well Microplate VWR Cat#734-2097
Density Gradient Buffer 1
Reagent Final Concentration Add to 1L
Sucrose 0.25 M 85.58 g
EDTA 6 mM 1.75 g
Tris base 60 mM 7.27 g
HCl 5 M n/a ~6.20 mL
Ultrapure water n/a Up to 1 L
Density Gradient Buffer 2
Reagent Final Concentration Add to 1L
Sucrose 0.25 M 85.58 g
EDTA 1 mM 0.29 g
Tris base 10 mM 1.21 g
HCl 5 M n/a ~1.05 mL
Ultrapure water n/a Up to 1 L
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 Filter the buffer by passing it through a vacuum-connected 0.22-mm bottle-top filter on top of a
sterile bottle.
Density gradient buffers can be stored at 4C for up to 6 months.
CRITICAL: HCl is highly corrosive. Avoid contact with eyes and skin. Use protective gog-
gles, gloves and clothing.
CRITICAL: To analyze the molecular complexity of urinary EV preparations by integrative
omics approaches (e.g. mass spectrometry based proteomics, RNA sequencing), the use
of ultrapure water (ASTM type 1) is a prerequisite to avoid interference with organic, bio-
logical and elemental contaminants. Avoid the use of deionized water (diH2O), which only
controls for ionic contaminants.
General requirements for Type 1 ultrapure water (ASTM D1193-06, 2011) are:
STEP-BY-STEP METHOD DETAILS
This protocol provides step-by-step instructions on performing density-based fractionation of urine
to prepare highly purified, multi-omics grade, urinary EV. Figure 2 highlights the 4 major steps of the
protocol. Urine samples are collected (1), pre-processed (2) and stored using validated standard
operating procedures. Bottom-up density gradient centrifugation of pre-processed urine separates
urinary EV from other extracellular particles (3). Finally, urinary EV are recovered from density




Urine samples are collected using a validated standard operating procedure.
1. Collect urine in a sterile container with a screw cap. Collect a mid-stream sample of random-catch
or second morning urine (50 mL).
Note: The use of second morning urine is recommended to minimize variability between do-
nors based on diurnal patterns and to omit the use of first morning urine collected from large
bladder residues.
Alternatives: If urine enriched in prostate-derived secretions is required, collect a first-catch
urine sample (50 mL) immediately following digital rectal examination (DRE). DRE is
Parameter Type 1 Reagent Water
Conductivity, max. mS/cm (25C) 0.056
Resistivity, min. MU-cm (25C) 18
pH, units (25C) n/a
Total Organic Carbon (TOC), max. (mg/L) 50
Sodium, max. (mg/L) 1
Chloride, max. (mg/L) 1
Total Silica, max. (mg/L) 3
Filter, min. mm 0.2
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performed by applying pressure on the prostate, depressing the surface1 cm, from the base
to the apex and from the lateral to the median line for each prostate lobe. Perform 3 finger
strokes per lobe (Figure 3) (Groskopf et al., 2006).
Figure 2. Illustrative Overview of the Urinary EV Separation Protocol
After collection and preparation of the urine sample, pre-enrichment of urinary EV is performed by ultrafiltration.
Urinary EV are separated and recovered from this ultrafiltrate by the orthogonal implementation of a bottom-up
density gradient and size-exclusion chromatography. The EV sample is concentrated to a volume suitable for
downstream EV characterization and integrative omics analysis.
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CRITICAL: Experiments using human biological specimens must conform to local and na-
tional regulations, and in accordance to the principles of the Helsinki Declaration. Written
informed consent must be obtained from urine sample donors. Strict compliance with
Biosafety Level 2 practices, containment equipment, and facilities are recommended
when handling human body fluids (U.S. Department of Health and Human Services; Cen-
ters for Disease Control; National Institutes of Health, 2009).
2. Perform test strip urinalysis to determine pathological changes in the collected urine sample.
Note: Bacterial contamination, urinary tract infection, hematuria and proteinuria may affect
downstream analysis of urinary EV.
Alternatives: Urinalysis can also be performed using an automated urine chemistry analyzer.
3. If immediate sample preparation after collection cannot be achieved, refrigerate the urine sample
at 4C.
CRITICAL: Correct preservation of urine samples before sample preparation is essential
to prevent microbial overgrowth, which can interfere with downstream urinary EV sepa-
ration and characterization.
CRITICAL: Do not freeze urine samples prior to sample preparation. This leads to cell lysis
and release of cell organelles into the sample.
Note: There is no consensus regarding short-term storage stability of urinary EV. Therefore,
we recommend Urine Sample Preparation within the same day, no later than 4 h after sample
collection (Yamamoto, 2010). The addition of protease inhibitors is not recommended, since




Urine samples are pre-processed and stored using validated standard operating procedures.
Figure 3. Standard Operating Procedure to Collect Urine Enriched in Prostatic Secretions
A first-catch urine sample is collected immediately following standardized digital rectal examination.
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4. Transfer the urine sample to a sterile 50 mL conical centrifugation tube.
5. Place the centrifugation tube into a pre-cooled benchtop centrifuge with swinging bucket rotor
and centrifuge at 1,000 3 g for 10 min at 4C. Counterbalance when needed.
6. Collect the supernatant, using an electronic pipettor and serological pipette, and transfer it to a
new sterile 50 mL conical centrifugation tube. Discard the pellet.
CRITICAL: Avoid transferring or disturbing the pellet, which contains cells and cell debris,
bacteria and urinary crystal precipitates.
Pause Point: Cell-free urine samples can be used immediately or stored at80C for up to 1
year.
Note: When collecting and storing urine samples in a biorepository, report all pre-analytical
and patient-related details according to the Biospecimen Reporting for Improved Study Qual-
ity (BRISQ) recommendations to better evaluate, interpret, compare, and reproduce experi-
mental results obtained with these samples (Moore et al., 2011).
Urinary EV Separation
Timing: 21 h
Urinary EV are separated from other extracellular particles using bottom-up density gradient
centrifugation.
When working with frozen urine samples that were stored in a biorepository, continue with step 7.
When working with fresh urine samples, jump to step 8.
Optional: To calculate recovery efficiencies and allow the normalization of quantitative results
between protocol runs, spike a control urine sample with a known amount of GFP-positive re-
combinant EV (rEV). These rEV can be tracked during separation from urine using fluores-
cence-, protein- or RNA based methods. For detailed instructions on the generation and
use of rEV, we refer to (Geeurickx et al., 2019).
7. Thaw the 50 mL urine sample at 20C–25C. After thawing, vortex the sample for 1 min.
CRITICAL: Urinary crystalline salts, such as calcium oxalate and amorphous phosphate or
urate crystals, precipitate at low storage temperatures. Crystal precipitation is observed
as an increased turbidity of the sample (Figure 4A). These precipitates interfere with
downstream EV separation. Therefore, urine samples containing crystal precipitates after
thawing require additional centrifugation at 1,000 3 g for 10 min at 4C, as described in
steps 5–6 of the protocol. The pellet will be pink in appearance (Figure 4B). Alternatively,
precipitates can be resolubilized by a 5 min temperature equilibration in a 37C water
bath or by correction of the urinary pH to 8.0 by addition of a 1 M Tris buffer (Yamamoto,
2010).
Note: Limit the amount of freeze-thaw cycles to one. Avoid repeated freeze-thaw cycles, since
this might negatively impact EV recovery from urine (Yuana et al., 2015).
8. Transfer the urine sample, using an electronic pipettor and serological pipette, into the sample
filter cup of an assembled 10-kDa Millipore Centricon Plus-70 centrifugal filter unit (Figure 5A).
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Note: The choice of centrifugal filter device for ultrafiltration is crucial and impacts the EV re-
covery efficiency of the protocol. Ultrafiltration devices equipped with a regenerated cellulose
membrane and a 10 kDa pore size recover EV the most efficiently (Vergauwen et al., 2017).
9. Place the filter unit into a pre-cooled benchtop centrifuge with swinging bucket rotor and centri-
fuge at 3,000 3 g for minimally 20 min at 4C until the sample is concentrated to at least 800 mL.
Counterbalance with a similar device when needed.
CRITICAL: Differences in concentration of urinary solutes due to donor fluid intake and
renal function, cause variability in centrifugation times between samples to obtain the
required sample volume. Overconcentration of the urine sample will negatively impact
EV recovery. Therefore, regular visual assessment of the concentrate at several time
points (e.g. 20, 25, 30 min, etc.) is critical. The target volume of 800 mL corresponds to
approximately 1 cm of remaining sample in the filter core (Figure 5B). See Problem 1 in
the Troubleshooting section.
10. Connect a concentrate collection cup to the sample filter cup, invert the device and place it in
the benchtop centrifuge. Counterbalance with a similar device when needed. Spin the concen-
trate down at 1,000 3 g for 2 min at 4C (Figure 5C).
Figure 4. Removal of Urinary Crystalline Salts
(A) Fresh urine sample (left) versus thawed urine sample containing crystal precipitates (right).
(B) Crystal precipitates are removed by centrifugation. The pellet (arrow) is pink in appearance.
Figure 5. Preparation of a Concentrated Urine Sample
(A) The cell-free urine sample is transferred into the sample filter cup of a centrifugal filter device (step 8).
(B) The sample is concentrated to a target volume of 800 mL, corresponding to ~1 cm of remaining sample in the filter
core (step 9).
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11. Remove the concentrate cup containing the concentrated urine sample from the sample filter
cup. Collect the sample with a pipette and, if necessary, correct the volume to 800 mL with
pre-cooled (4C) Density Gradient Buffer 2. Transfer to a 5 mL Eppendorf tube and place on ice.
CRITICAL: The concentrated urine sample will form the basis for the preparation of a 40%
(w/v) iodixanol sample suspension in step 14 of the protocol. It is critical that the volume
of this sample is exactly 800 mL in order to prepare the suspension correctly.
12. Prepare the iodixanol working solution (50% w/v) by mixing 1 volume of Density Gradient Buffer
1 with 5 volumes of OptiPrep in a 50 mL conical tube according to the following table. Keep the
working solution cooled on ice.
Note: Fresh working solution should be prepared for each experiment. Protect Optiprep from
prolonged exposure to direct sunlight, since this leads to release of iodine from the iodixanol
molecule.
13. Prepare 5%, 10% and 20% (w/v) iodixanol solutions by mixing appropriate volumes of working
solution (50% w/v) and Density Gradient Buffer 2 in 50 mL conical tubes according to the
following table. Turn the tubes gently up and down until homogeneous solutions have been ob-
tained. Keep the solutions cooled on ice.
Note: Fresh solutions should be prepared for each experiment.
14. Prepare a 40% (w/v) iodixanol sample suspension by adding 3.2 mL of iodixanol working solu-
tion (50% w/v) to the concentrated urine sample (800 mL), prepared in step 11 of the protocol.
Homogenize the mixture by gently pipetting up and down.
CRITICAL: Gentle pipetting to homogenize the 40% (w/v) iodixanol sample suspension is a
prerequisite to avoid the introduction of air bubbles, which may disturb the density layers
of the gradient (Figure 6).








5 (% w/v) 10 (% w/v) 20 (% w/v)
Working
Solution (mL)
Buffer 2 (mL) Working
Solution (mL)
Buffer 2 (mL) Working
Solution (mL)
Buffer 2 (mL)
1 0.5 4.5 1.0 4.0 2.0 3.0
2 1.0 9.0 2.0 8.0 4.0 6.0
3 1.5 13.5 3.0 12.0 6.0 9.0
4 2.0 18.0 4.0 16.0 8.0 12.0
5 2.5 22.5 5.0 20.0 10.0 15.0
6 3.0 27.0 6.0 24.0 12.0 18.0
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15. Prepare a discontinuous density gradient in a clean 17 mL Thinwall polypropylene tube by layer-
ing iodixanol solutions with successively lower densities on top of each other.
Timing: 10–20 min per density gradient
a. Hold the tube upright and gently dispense the 4mL of 40% (w/v) iodixanol sample suspension,
prepared in step 15 of the protocol, to the bottom of the tube.
b. Carefully tilt the tube to 70. Gently dispense 4 mL of the 20% (w/v) iodixanol solution to the
surface of the liquid close to the opening of the tube. Keep the pipette tip close to the wall of
the tube.
Note: transferring the solution dropwise using a P1000 pipette (4 3 1,000 mL) provides a slow
and smooth flow of liquid.
c. Gently dispense 4 mL of the 10% (w/v) iodixanol solution to the surface of the liquid close to
the opening of the tube. Keep the pipette tip close to the wall of the tube.
Note: transferring the solution dropwise using a P1000 pipette (4 3 1,000 mL) provides a slow
and smooth flow of liquid.
d. Gently dispense 3.5 mL of the 5% (w/v) iodixanol solution to the surface of the liquid close to
the opening of the tube. Keep the pipette tip close to the wall of the tube.
Note: transferring the solution dropwise using a P1000 pipette (4 3 875 mL) provides a slow
and smooth flow of liquid.
e. Gently dispense 1.0 mL of PBS to the surface of the liquid close to the opening of the tube.
Keep the pipette tip close to the wall of the tube.
f. Place the density gradient upright in a tube rack on ice or in a pre-cooled (20C) aluminum
cooling block.
CRITICAL: Keep the work area free from vibrations and disturbances. Dispense the iodix-
anol solutions carefully to avoid mixing and ensure the formation of distinct layers with a
sharp interface (Figure 7). Do not repeatedly shift between holding the tube tilted and up-
right, since this negatively affects gradient layering (Methods Video S1). See Problem 2 in
the Troubleshooting section.
Figure 6. Preparation of a 40% Iodixanol Sample Suspension
(A) The suspension is homogenized by gently mixing the concentrated urine sample and the appropriate volume of
iodixanol working solution (step 14).
(B) Imprudent homogenization of the suspension generates air bubbles and should be avoided.
ll
OPEN ACCESS
STAR Protocols 1, 100073, September 18, 2020 11
Please cite this article in press as: Dhondt et al., Preparation of Multi-omics Grade Extracellular Vesicles by Density-Based Fractionation of Urine,
STAR Protocols (2020), https://doi.org/10.1016/j.xpro.2020.100073
Protocol
Alternatives: Robot-assisted layering of discontinuous density gradients eliminates user vari-
ability, is less time-consuming, and contributes to consistent and reproducible density-based
EV separation from urine. In case an automated liquid handler with liquid level sensing (e.g.
Biomek 4000Workstation) is available to the researcher, we recommend robot-assisted prep-
aration of density gradients. For detailed instructions on automated gradient layering, we
refer to (Tulkens et al., 2019).
16. Place the SW 32.1 Ti rotor into the ultracentrifuge.
17. Gently place the density gradient(s), prepared in step 16, into the rotor bucket.
18. Gently place the rotor buckets into the rotor. Counterbalance when needed.
19. Program the ultracentrifuge run using the following settings:
a. Rotor type: SW 32.1 Ti Rotor
b. Type of centrifugation tube: 17 mL Thinwall
c. Speed: 100,000 3 g
d. Time: 18 h
e. Temperature: 4C
f. Acceleration: 0 (MAX)
g. Deceleration: 9
20. Start the ultracentrifuge.
Pause Point: Plan the ultracentrifuge run as an overnight run and continue the protocol the
next day.
21. After completion of the ultracentrifuge run, carefully transfer the rotor buckets into a rack.
Figure 7. Successful Preparation of a Discontinuous Bottom-Up Density Gradient
The iodixanol solutions form distinct layers (arrows) with a sharp interface (step 15).
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22. Take the fractionated density gradient out of the bucket and collect the fractions from top to
bottom.
Timing: 10–15 min per density gradient
a. Hold the tube upright. Gently place the pipette tip on the center of the fluid meniscus of the
density gradient and carefully collect individual 1 mL fractions from the top of the gradient.
CRITICAL: Collection of density gradient fractions is technically challenging and prone to
error. Hold the centrifugation tube between your thumb and index finger to ensure the
tube stays upright during the entire process. Use a P1000 pipette with smooth and pre-
cise aspiration control (Methods Video S2).
b. Transfer the collected density gradient fractions to sterile 1.5 mL Eppendorf tubes and keep
them cooled on ice.
Alternatives: As outlined in step 15, robot-assisted collection of density gradient fractions has
several advantages over manual collection, contributing to standardization and reproduc-
ibility of the protocol by eliminating user variability. In case an automated liquid handler
with liquid level sensing (e.g. Biomek 4000 Workstation) is available to the researcher, we
highly recommend robot-assisted collection of density gradient fractions. For detailed in-
structions on automated gradient fractionation, we refer to (Tulkens et al., 2019).
Optional: Determine the final density of the fractions collected from a blank control gradient
using a multi-well plate reader.
(i) Transfer 200 mL of density gradient buffer 2 in the well of a 96-well microplate to use as a
blank
(ii) Transfer 100 mL of 5%, 10%, 20% and 40% iodixanol solutions into 100 mL of diH2O in the
wells of a 96-well microplate to make 1:1 aqueous dilutions
(iii) Transfer 100 mL of each of the fractions into 100 mL of diH2O in the wells of a 96-well plate
microplate to make 1:1 aqueous dilutions
(iv) Place the 96-well plate in a multi-well plate reader and measure the absorbance values at
340 nm of the solutions in each well
(v) Calculate the density of the gradient fractions using a standard curve of the absorbance
values of the aqueous dilutions of 5, 10, 20 and 40% iodixanol solutions. Corresponding
densities of the iodixanol solutions (in 0.25 M sucrose) are provided in the table:
Note: For iodixanol concentrations above 35% (w/v), it may be necessary tomake a second 1:1
aqueous dilution to avoid absorbance values above 1.2.
23. Pool density gradient fractions 9–10, enriched in urinary EV, and continue with urinary EV recovery.
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Optional: Other density gradient fractions can be collected and processed in function of the
intended research objective. Soluble urinary proteins are enriched in high-density fractions
14–16 (Dhondt et al., 2020).
Urinary EV Recovery
Timing: 30 min per sample
EV are recovered from density gradient fractions using size-exclusion chromatography.
Note: Several methods can be used for urinary EV recovery from density gradient fractions
(e.g. SEC and ultracentrifugation). However, complete separation of the iodixanol matrix
from EV can only be guaranteed using size-exclusion chromatography (SEC) (Vergauwen
et al., 2017). Since iodixanol remnants in urinary EV preparations interfere with downstream
mass spectrometry-based proteomics and RNA sequencing, complete removal is desirable.
In addition, the efficiency of EV recovery from density gradient fractions by SEC is higher
compared to that of EV recovery by ultracentrifugation. Therefore, if the final goal of urinary
EV separation is performing integrative omics profiling, SEC should be used in order to obtain
maximal EV purity and yield, qualitative tandem mass spectra for mass spectrometry-based
proteomics, and optimal sequencing quality and depth for RNA sequencing.
24. Size-exclusion Chromatography
a. Clamp the SEC column to a laboratory stand (See Materials and Equipment for instructions
on how to prepare SEC columns). Check if the column did not dry out and remove the closing
cone (Figure 8).
b. Rinse the column with 2mL of pre-cooled PBS (4C). Collect the eluate in a translucent vial and
confirm the column does not leak Sepharose resin. See Problem 3 in the Troubleshooting
section.
c. Load pooled density fractions 9–10 (2 mL), collected in steps 22–23 of the protocol, onto the
column as soon as the PBS buffer has completely disappeared into the resin.
CRITICAL: When loading PBS or sample onto the column, ensure not to disturb the Se-
pharose resin in the column. Load dropwise and close to the surface of the resin. Ensure
a slow and smooth flow of liquid. Make sure the SEC column does not dry out (Methods
Video S3).
d. Immediately following sample loading onto the SEC column, start collecting individual frac-
tions of 1 mL. SEC fractions 1–3 are void volume, while EV elute in SEC fractions 4–7. When
the loaded sample has completely disappeared into the resin, load PBS buffer onto to column
as long as it takes to collect the SEC fractions of interest and to prevent the column from drying
out.
Note: Collect the first 3 mL of eluate (SEC fractions 1–3) in a 5 mL Eppendorf tube and collect
the next 4 mL of eluate (SEC fractions 4–7 containing EV) in a separate 5 mL Eppendorf tube.
e. Transfer SEC fractions 4–7 into a 10-kDa centrifugal filter unit.
Note: The choice of centrifugal filter device for ultrafiltration is crucial and impacts the EV re-
covery efficiency of the protocol. Ultrafiltration devices equipped with a regenerated cellulose
membrane and a 10 kDa pore size recover EV the most efficiently (Vergauwen et al., 2017).
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f. Place the filter unit into a pre-cooled benchtop centrifuge with swinging bucket rotor and
centrifuge at 3,000 3 g at 4 C until the sample is concentrated to 100 mL (10–30 min). Coun-
terbalance with a similar device when needed.
g. Collect the concentrated urinary EV sample by a reverse spin at 1,000 3 g for 2 min at 4C.
Transfer to a 1.5 mL Eppendorf tube and place on ice.
Pause Point: Urinary EV can be characterized immediately or stored at 80C for several
months.
Urinary EV Preparation for Integrative Omics Profiling
Urinary EV samples are prepared for integrative omics profiling.
Note: we provide different procedures for urinary EV preparation for integrative omics
profiling. However, a detailed step-by-step description of these methods is outside the scope
of this protocol. The approach to downstream sample processing is at the discretion of the
researcher.
25. Prepare urinary EV samples for mass spectrometry-based proteomic analysis (a) and/or RNA
sequencing (b). A 100 mL urinary EV suspension is sufficient for both downstream applications.
a. Perform protein extraction and tryptic digestion of the urinary EV sample for mass spectrom-
etry-based proteomics by filter-aided sample preparation (FASP) (Dhondt et al., 2020;
Wisniewski et al., 2009). Desalt the peptides and proceed to liquid chromatography–mass
spectrometry (LC-MS/MS).
b. Perform RNA extraction of the urinary EV sample for RNA sequencing by spin column-based
purification of total RNA (eg. miRNeasy Serum/Plasma Kit – Qiagen – Cat# 217184). We
recommend the use of Sequin (Hardwick et al., 2016) and ERCC (ThermoFisher – Cat#
4456740) RNA spikes to control for variation in RNA isolation and RNA expression data,
respectively. Proceed to library preparation and RNA sequencing.
Figure 8. Size-Exclusion Chromatography Quality
Assurance
Prior to or during SEC, the column should be
prevented from drying out (step 24).
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EXPECTED OUTCOMES
Consistent characterization of urinary EV preparations by multiple, complementary methods is
essential to analyze the performance of the protocol, as well as its specificity and repeatability
(De Wever and Hendrix, 2019). We advise to characterize urinary EV in compliance with EV-TRACK
(Van Deun et al., 2017) and MISEV2018 guidelines (Théry et al., 2018) prior to downstream integra-
tive omics profiling (e.g. mass-spectrometry based proteomics and RNA sequencing). We recom-
mend a combination of complementary particle- and protein-based measurement methods to
obtain a quantitative and qualitative assessment of urinary EV. Western blot (or ELISA) confirms
the enrichment of EV-associated proteins and depletion of non-EV-associated proteins such as uri-
nary high-molecular weight proteins. Total particle number and size distribution are measured by
light scattering methods such as nanoparticle tracking analysis (NTA). EV ultrastructure, integrity
and purity are evaluated by electron microscopy (EM). For detailed instructions on how to perform
EV characterization, we refer to (Tulkens et al., 2019).
EV-enriched density gradient fractions are defined by distinct physical and biochemical characteristics
(Figures 9 and 10). Urinary EV (1.087–1.109 g/mL) differ in buoyant density from Tamm-Horsfall protein
(THP) polymers (1.156–1.201 g/mL) and protein aggregates (1.207–1.231 g/mL) (Figure 9). Western blot
analysis reveals the presence of EV-enriched proteins (e.g. ALIX, TSG-101, Flotillin-1, Syntenin-1, CD9)
and depletion of non-EV-enriched proteins (e.g. GM130, THP, PMP70). In addition, urinary EV are en-
riched in proteins associatedwith the specific genitourinary organs they are derived from, such as PODXL
and AQP2 (kidney), UPK1B (urinary bladder) and KLK3/PSA (prostate) (Figure 10A). The total urinary EV
yield and size distribution profile is obtained by NTA (NTA-specific size range: 90–250 nm) (Figure 10B).
An overall high urinary EV yield can be expected, but is variable depending on sample volume, time of
collection, hydration status and renal function (Dhondt et al., 2018). In our experience, 1.03 109–5.03
1010 EV per mL urine are obtained, corresponding to an EV-derived protein recovery of 0.1–4.0 mg per
mL urine. The combination of bottom-up density-gradient centrifugation and SEC achieves an average
urinary EV recovery efficiency of 30% (Dhondt et al., 2020; Geeurickx et al., 2019). In general, urinary EV
preparations obtained by this protocol contain 1.03 1010 particles per mg of protein, corresponding to
high-purity urinary EV preparations (Webber and Clayton, 2013). Transmission electron microscopy
(TEM) uncovers urinary EV ultrastructure and identifies extensive numbers of vesicles (TEM-specific
size range: 30–250 nm) surrounded by a lipid bilayer, in the absence of polymeric THP networks and pro-
tein complexes (Figure 10C).
Figure 9. Density Gradient Centrifugation to Separate Urinary EV from Tamm-Horsfall Protein Polymers and
Soluble Proteins
Density of the collected fractions as determined by 340 nm absorbance. EV (1.087–1.109 g/mL) differ in buoyant
density from Tamm-Horsfall protein polymers (1.156–1.201 g/mL) and protein aggregates (1.207–1.231 g/mL).
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Integrative omics profiling enables researchers to unravel the molecular complexity of urinary EV.
Mass spectrometry-based proteomics reveals the enrichment of a variety of endosomal, cytosolic
andmembrane-derived proteins (Dhondt et al., 2020), while RNA sequencing identifies distinct clas-
ses of RNA molecules, including mRNA, miRNA, lncRNA and circRNA (Everaert et al., 2019).
We demonstrated the ability of this protocol to separate urinary EV with high specificity and repeat-
ability, which is a prerequisite to obtain reliable multi-omics data for clinical and research applica-
tions. For full details, we refer to (Dhondt et al., 2020).
LIMITATIONS
While this protocol was developed to recover urinary EV with high specificity and repeatability, a
prerequisite to accurately map their biochemical composition, the long turn-around time and low-
throughput aspect of a density gradient approach, as well as the need for relatively high sample
volumes, limits its use beyond a scientific research setting. The implementation of density-based
urinary EV separation also requires technical expertise andmight be prone to replication bias in inex-
perienced hands. Urine is a diluted solution with a relatively low absolute concentration of EV (Web-
ber and Clayton, 2013). Therefore, pre-enrichment of EV by ultrafiltration, starting from a sufficiently
high volume of urine (30–50 mL) is necessary in order to generate a useful quantity of EV for down-
stream integrative omics analysis and should be considered when creating biorepositories for the
study of urinary EV.
EV can be separated from urine using techniques different from the one described in this protocol.
According to the EV-TRACK knowledgebase (Van Deun et al., 2017), serial ultracentrifugation (Pisit-
kun et al., 2004), polymer-based precipitation (Alvarez et al., 2012) and size-exclusion chromatog-
raphy (Lozano-Ramos et al., 2015) are the most frequently used. In addition, ultrafiltration (Vergau-
wen et al., 2017), microfluidics- (Liang et al., 2017) and immunoaffinity-based methods (Islam et al.,
2019; Mussack et al., 2019) and flow cytometric sorting (Campos-Silva et al., 2019) have been
applied for urinary EV separation. The separation method of choice is guided by a tradeoff between
efficiency and the degree of EV-specificity required to answer the experimental question
(Théry et al., 2018). Despite the incompatibility between density-gradient centrifugation and
Figure 10. Characterization of Urinary EV Preparations by Protein- and Particle-Based Analysis Methods
(A) The presence of (tissue-specific) EV-enriched or depletion of non-EV-enriched proteins is assessed by western blot
analysis.
(B) EV yield and size-distribution profile are obtained by nanoparticle tracking analysis. The NTA calculated size
distribution is depicted as mean (black line) with standard error (red area) and total particle number, mean particle
size and mode are shown.
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Figure 11. Troubleshooting
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high-throughput sample processing, the implementation of this step is critical to separate urinary EV
with high specificity from other components such as Tamm-Horsfall protein polymers and urinary
protein aggregates. A similar level of specificity cannot be realized with alternative separation
methods available to date (Van Deun et al., 2014; Dhondt et al., 2020). However, certain limitations
of a density gradient approach can be overcome by automation of gradient layering and fraction
collection, rendering the process reproducible, robust, operator-independent and less time
consuming (Tulkens et al., 2019). The use of biological reference materials such as trackable GFP-
positive rEV assists in mitigating technical variation introduced during sample preparation and anal-
ysis (Geeurickx et al., 2019).
Although the potential impact of various pre-analytical factors during clinical sample processing on
EV studies is increasingly recognized, this issue has not been fully addressed in this protocol. For
collection, handling and storage of urine samples, we recommend following the tentative standard
operating procedure provided by the Human Kidney and Urine Proteome Project (HKUPP) from the
Human Proteome Organization (HUPO) (Yamamoto, 2010). Finally, normalized analysis of EV is
important to allow patient-to-patient comparison of samples. To which extent the intrinsic inter-
and intrasubject variability of urine is reflected in urinary EV is not clear. Various methods of normal-
ization have been described, including urinary flow rate and volume, urinary creatinine and protein
concentration, particle numbers and EV-enriched protein (CD9, ALIX, PSA) signal (Dhondt et al.,




Insufficient removal of crystal precipitates from the urine sample may cause obstruction of the filter
pores. This will result in a significantly slower or ineffective clearance of the urine sample trough the
filter. Pink precipitates can be observed on the filter membrane (Figure 11A).
Potential Solution
Collect the remaining urine sample from the sample filter cup. Remove the crystal precipitates by
centrifugation, as described in step 8 of the protocol and transfer the supernatant to a new centrif-
ugal filter device.
Problem 2
Manual gradient layering is technically challenging. Improper handling of the layering technique
may result in mixing of the iodixanol solutions and reduce the resolving power of the gradient. If
this is the case, no distinct interface can be observed between the gradient layers (Figure 11B).
Potential Solution
Prepare a new density gradient. Researchers with limited experience in making density gradients are
recommended to familiarize themselves with the procedure by preparing colored test gradients.
Add 50 mL of 0.4% (w/v) trypan blue solution to the 10% and 40% (w/v) iodixanol solutions. A sharp
interface should be observed between the different layers of the gradient.
Problem 3
When a SEC column has been incorrectly prepared, Sepharose resin may leak out of the syringe into
the eluate. This may interfere with the separation of the sample components and downstream ana-
lyses (Figure 11C).
Figure 11. Continued
(B) Mixed iodixanol solutions and the absence of a clear interface (arrows) between layers (left) versus correct gradient
layering and the presence of a clear interface (arrows) between layers (right).
(C) Presence of Sepharose resin in the SEC eluate (left) versus normal appearance of the eluate (right).
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Potential Solution
Prepare a new SEC column. A Sepharose leak is usually caused by incorrect placement of the nylon-
net filter on the bottom of the syringe. Ensure that the filter sufficiently covers the opening of the
syringe nozzle. Wetting the filter with PBS might allow more accurate manipulation. Carefully add
the Sepharose resin to the syringe.
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Lamminmäki, U. (2019). A nanoparticle-based
approach for the detection of extracellular vesicles.
Sci. Rep. 9, 10038.
Liang, L.G., Kong, M.Q., Zhou, S., Sheng, Y.F.,
Wang, P., Yu, T., Inci, F., Kuo, W.P., Li, L.J., Demirci,
U., et al. (2017). An integrated double-filtration
microfluidic device for isolation, enrichment and
quantification of urinary extracellular vesicles for
detection of bladder cancer. Sci. Rep. 7, 46224.
Lozano-Ramos, I., Bancu, I., Oliveira-Tercero, A.,
Armengol, M.P., Menezes-Neto, A., Del Portillo,
H.A., Lauzurica-Valdemoros, R., and Borràs, F.E.
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